A型激酶锚定蛋白介导的心肌肥厚调控机制的研究进展

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (11): 1304-1308.

A型激酶锚定蛋白介导的心肌肥厚调控机制的研究进展

王政，汪和贵

皖南医学院附属弋矶山医院心内科，芜湖 241000，安徽

收稿日期:2017-06-05 修回日期:2017-06-22 出版日期:2017-11-26 发布日期:2017-12-11
通讯作者: 汪和贵，男，博士，主任医师，硕士生导师，研究方向：心血管临床与冠状动脉介入治疗。 Tel：13855309290 E-mail：wangheguiqd@sina.com
作者简介:王政，男，在读硕士生，研究方向：心血管临床与冠状动脉介入治疗。 Tel：18555139792 E-mail：1242644416@qq.com
基金资助:
安徽省高校自然科学研究重大项目（KJ2015ZD42）；皖南医学院弋矶山医院引进人才项目（YR201615）

Research progress of A-kinase-anchoring protein mediated regulation of cardiac hypertrophy

WANG Zheng, WANG Hegui

Department of Cardiology, Yijishan Hospital Affiliated to Wannan Medical College, Wuhu 241000, Anhui, China

Received:2017-06-05 Revised:2017-06-22 Online:2017-11-26 Published:2017-12-11

摘要/Abstract

摘要：

心肌肥厚是心脏在应激情况下的代偿反应，生理性心肌肥厚可以提高心脏的生理功能，但病理性的心肌肥厚会对心脏造成一系列不利的影响，如发生心律失常、心衰及猝死等危险。最近多项研究发现，A型激酶锚定蛋白（AKAPs）协同多种信号因子参与病理性心肌肥厚的调节过程，本文就AKAPs对病理性心肌肥厚的调控机制及临床意义作一综述。

关键词: A型激酶锚定蛋白, 心肌肥厚, mAKAP, AKAP121, AKAP-Lbc

Abstract:

Cardiac hypertrophy is the compensatory response of the heart in response to stimulation. Cardiac hypertrophy can improve the physiological function of the heart, but pathological myocardiac hypertrophy can cause a series of adverse effects on the heart such as arrhythmia, heart failure and sudden death risk. Recent studies revealed that AKAPs participates in the regulation of pathological myocardiac hypertrophy with multiple signal factors. Here we review the role of the A-kinase anchoring protein (AKAPs) in the regulation of pathological hypertrophy and its clinical significance.

Key words: A-kinase-anchoring protein, myocardiac hypertrophy, mAKAP, AKAP121, AKAP-Lbc

中图分类号:

R542.2

王政，汪和贵. A型激酶锚定蛋白介导的心肌肥厚调控机制的研究进展[J]. 中国临床药理学与治疗学, 2017, 22(11): 1304-1308.

WANG Zheng, WANG Hegui. Research progress of A-kinase-anchoring protein mediated regulation of cardiac hypertrophy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1304-1308.

参考文献

［1］Riaz S, Zeidan A, Mraiche F. Myocardial proteases and cardiac remodeling［J］. J Cell Physiol, 2017, 232(12): 3244-3250.
［2］Zhao L, Wu D, Sang M, et al. Stachydrine ameliorates isoproterenol-induced cardiac hypertrophy and fibrosis by suppressing inflammation and oxidative stress through inhibiting NF-kappaB and JAK/STAT signaling pathways in rats［J］. Int Immunopharmacol, 2017, 48: 102-109.
［3］Welch EJ, Jones BW, Scott JD. Networking with AKAPs: context-dependent regulation of anchored enzymes［J］. Mol Interv, 2010, 10(2): 86-97.
［4］Pawson CT, Scott JD. Signal integration through blending, bolstering and bifurcating of intracellular information［J］. Nat Struct Mol Biol, 2010, 17(6): 653-658.
［5］Scott JD, Dessauer CW, Tasken K. Creating order from chaos: cellular regulation by kinase anchoring［J］. Annu Rev Pharmacol Toxicol, 2013, 53: 187-210.
［6］Diviani D, Maric D, Perez Lopez I, et al. A-kinase anchoring proteins: molecular regulators of the cardiac stress response［J］. Biochim Biophys Acta, 2013, 1833(4): 901-908.
［7］Skroblin P, Grossmann S, Schafer G, et al. Mechanisms of protein kinase A anchoring［J］. Int Rev Cell Mol Biol, 2010, 283: 235-330.
［8］Beene DL, Scott JD. A-kinase anchoring proteins take shape［J］. Curr Opin Cell Biol, 2007, 19(2): 192-198.
［9］Carnegie GK, Burmeister BT. A-kinase anchoring proteins that regulate cardiac remodeling［J］. J Cardiovasc Pharmacol, 2011, 58(5): 451-458.
［10］Abrenica B, Alshaaban M, Czubryt MP. The A-kinase anchor protein AKAP121 is a negative regulator of cardiomyocyte hypertrophy［J］. J Mol Cell Cardiol, 2009, 46(5): 674-681.
［11］Carnegie GK, Soughayer J, Smith FD, et al. AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway［J］. Mol Cell, 2008, 32(2): 169-179.
［12］ Perez Lopez I, Cariolato L, Maric D, et al. A-kinase anchoring protein Lbc coordinates a p38 activating signaling complex controlling compensatory cardiac hypertrophy［J］. Mol Cell Biol, 2013, 33(15): 2903-2917.
［13］Kritzer MD, Li J, Passariello CL, et al. The scaffold protein muscle A-kinase anchoring protein beta orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure［J］. Circ Heart Fail, 2014, 7(4): 663-672.
［14］Scott JD, Pawson T. Cell signaling in space and time: where proteins come together and when they're apart［J］. Science, 2009, 326(5957): 1220-1224.
［15］Rababa'h A, Craft JW Jr, Wijaya CS, et al. Protein kinase A and phosphodiesterase-4D3 binding to coding polymorphisms of cardiac muscle anchoring protein (mAKAP)［J］. J Mol Biol, 2013, 425(18): 3277-3288.
［16］Passariello CL, Li J, Dodge-Kafka K, et al. mAKAP-a master scaffold for cardiac remodeling［J］. J Cardiovasc Pharmacol, 2015, 65(3): 218-225.
［17］Zhang L, Malik S, Pang J, et al. Phospholipase Cepsilon hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy［J］. Cell, 2013, 153(1): 216-227.
［18］Xie M, Hill JA. HDAC-dependent ventricular remodeling［J］. Trends Cardiovasc Med, 2013, 23(6): 229-235.
［19］Liu Q, Hofmann PA. Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apoptosis of cardiac myocytes［J］. Am J Physiol Heart Circ Physiol, 2004, 286(6): H2204-H2212.
［20］Dodge-Kafka KL, Kapiloff MS. The mAKAP signaling complex: integration of cAMP, calcium, and MAP kinase signaling pathways［J］. Eur J Cell Biol, 2006, 85(7): 593-602.
［21］Li J, Kritzer MD, Michel JJ, et al. Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy［J］. Circ Res, 2013, 112(1): 128-139.
［22］Martinez EC, Passariello CL, Li J, et al. RSK3: A regulator of pathological cardiac remodeling［J］. IUBMB Life, 2015, 67(5): 331-337.
［23］Cavin S, Maric D, Diviani D. A-kinase anchoring protein-Lbc promotes pro-fibrotic signaling in cardiac fibroblasts［J］. Biochim Biophys Acta, 2014, 1843(2): 335-345.
［24］ Cariolato L, Cavin S, Diviani D. A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling complex involved in alpha1-adrenergic receptor-induced p38 activation［J］. J Biol Chem, 2011, 286(10): 7925-7937.
［25］Marber MS, Rose B, Wang Y. The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure［J］. J Mol Cell Cardiol, 2011, 51(4): 485-490.
［26］Streicher JM, Ren S, Herschman H, et al. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart［J］. Circ Res, 2010, 106(8): 1434-1443.
［27］Del Vescovo CD, Cotecchia S, Diviani D. A-kinase-anchoring protein-Lbc anchors IkappaB kinase beta to support interleukin-6-mediated cardiomyocyte hypertrophy［J］. Mol Cell Biol, 2013, 33(1): 14-27.
［28］Smith FD, Scott JD. A-kinase-anchoring protein-Lbc connects stress signaling to cardiac hypertrophy［J］. Mol Cell Biol, 2013, 33(1): 2-3.
［29］Spindler MJ, Burmeister BT, Huang Y, et al. AKAP13 Rho-GEF and PKD-binding domain deficient mice develop normally but have an abnormal response to beta-adrenergic-induced cardiac hypertrophy［J］. PLoS One, 2013, 8(4): e62705.
［30］Taglieri DM, Johnson KR, Burmeister BT, et al. The C-terminus of the long AKAP13 isoform (AKAP-Lbc) is critical for development of compensatory cardiac hypertrophy［J］. J Mol Cell Cardiol, 2014, 66: 27-40.
［31］Johnson KR, Nicodemus-Johnson J, Spindler MJ, et al. Genome-wide gene expression analysis shows AKAP13-mediated PKD1 signaling regulates the transcriptional response to cardiac hypertrophy［J］. PLoS One, 2015, 10(7): e0132474.
［32］Barry SP, Townsend PA. What causes a broken heart-molecular insights into heart failure［J］. Int Rev Cell Mol Biol, 2010, 284: 113-179.
［33］Edwards HV, Scott JD, Baillie GS. The A-kinase-anchoring protein AKAP-Lbc facilitates cardioprotective PKA phosphorylation of Hsp20 on Ser(16)［J］. Biochem J, 2012, 446(3): 437-443.
［34］Schiattarella GG, Cattaneo F, Pironti G, et al. Akap1 deficiency promotes mitochondrial aberrations and exacerbates cardiac injury following permanent coronary ligation via enhanced mitophagy and apoptosis［J］. PLoS One, 2016, 11(5): e0154076.

[1]	黄霆，汪和贵. β受体-PKA-AKAP信号通路调控心力衰竭的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(5): 592-596.
[2]	李忠洪，王平，周四桂，王桂香. 二甲双胍通过上调谷胱甘肽-S-转移酶μ₂抑制大鼠心肌肥厚[J]. 中国临床药理学与治疗学, 2017, 22(12): 1326-1331.
[3]	张莹，王安才，王新，王德国，邢文. 阿托伐他汀对腹主动脉缩窄性高血压大鼠心肌组织蛋白酶S、K的影响[J]. 中国临床药理学与治疗学, 2016, 21(9): 968-972.
[4]	周四桂, 徐立朋, 路遥, 袁茜, 潘雪刁, 臧林泉. 非诺贝特通过上调短链酰基辅酶A脱氢酶抑制大鼠心肌肥厚[J]. 中国临床药理学与治疗学, 2013, 18(8): 868-873.
[5]	黄建寨, 魏立, 王晓军, 李庆平. 高血压大鼠心肌肾素-血管紧张素系统的日变化[J]. 中国临床药理学与治疗学, 2006, 11(8): 863-867.
[6]	梁绪国, 张岫美. 血管紧张素转化酶抑制剂与血管紧张素受体拮抗剂合用对腹主动脉狭窄高血压大鼠心肌肥厚的影响[J]. 中国临床药理学与治疗学, 2006, 11(10): 1133-1136.
[7]	曾量波, 梁子敬, 王鹏鲲, 叶政, 陈国勤, 卢敏俊. 阿司匹林对压力负荷性心肌肥厚大鼠左心室重构的影响[J]. 中国临床药理学与治疗学, 2005, 10(7): 787-790.
[8]	张捷, 刘昌慧, 何勇, 魏春阳, 王绍华. 缬沙坦对自发性高血压大鼠心肌抑癌基因PTEN 表达的影响[J]. 中国临床药理学与治疗学, 2004, 9(9): 988-991.
[9]	严玲, 王晋明, 王芳, 梁远红, 夏芳, 宋晓华. β₁ 肾上腺素能受体反义寡核苷酸对肾性高血压大鼠血流动力学及心肌肥厚的影响[J]. 中国临床药理学与治疗学, 2004, 9(9): 997-1001.
[10]	张铖, 叶平, 张洁. 吡格列酮对左心室肥厚大鼠心肌炎性细胞因子表达的影响[J]. 中国临床药理学与治疗学, 2004, 9(6): 658-661.
[11]	涂欣, 王晋明, 涂乾, 涂晋文. 白花前胡提取物对腹主动脉缩窄大鼠心室重构及Bcl-2、Bax 蛋白表达的影响[J]. 中国临床药理学与治疗学, 2004, 9(4): 394-398.
[12]	段小春, 王晋明, 王芳, 李恒, 秦晋梅. 缬沙坦和螺内酯对高血压大鼠心肌胰岛素样生长因子-1 的作用[J]. 中国临床药理学与治疗学, 2004, 9(10): 1137-1141.
[13]	林岚, 洪华山, 陈若函, 王一波, 江琼. 胰岛素在培养的乳鼠心肌成纤维细胞对纤维连接蛋白、层粘连蛋白和转化生长因子β₁ 表达的影响¹[J]. 中国临床药理学与治疗学, 2003, 8(1): 18-22.
[14]	汤海, 胡作英, 杨霆. 不同剂量valsartan应用对SHR血压和左室心肌肥厚的影响[J]. 中国临床药理学与治疗学, 2001, 6(1): 12-14.